Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

First ever study of human stem cell treatment

The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.

New study of toxins and heart disease

Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

New member to Active board

The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.

Less scars with new product

A new Swedish product for post surgical scar formation enters clinical development.

Biovitrum sells UK part

Biovitrum will soon spin-out a British subsidary

EU says yes to Roche drug

EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.

Metabolic pro heads prefect post

The dean of the Department of Biomedicine at the Sahlgrenska Academy has appointed a new assistant prefect.

Oasmia gets a confirmation

FDA has granted Oasmia an expedited review status for Paclical Vet.

Respiratorius hunts millions

The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.

Biotech goes white and bright

White biotech could become Denmark's next blossoming business area.

Finnish-Dutch engineering cooperation continues

The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.

LEO Pharma - International Clinical Trial Manager

Travelling scholarship to DTU professor

The Vera og Carl Johan Michaelsens Rejselegat has the founder of the Medicine and Technology program at DTU with a scholarship.

Laboratorieassistent till Olink

DKK 1,3 billion for grand research

Danish Councils for Independent Research, DFF, will grant DKK 1,3 billion during 2009. Now has the application period started.

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

Collaboration brings next generation drugs

Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.

New influenza vaccine to EU

The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.

Martin Bergö: "The Idea is the Thing"

Martin Bergö, 38, goes wherever ideas take him - it's a process that has led to, and resulted from, plenty of unexpected results. Those ideas have been recognized as good ones: in 2008, he was awarded the Eric K. Fernström Foundation's Prize for young researchers. It isn't the first award for the Associate Professor at Gothenburg University's Sahlgrenska Academy. In 2007, he received a grant award of 16 million SEK from the European Research Council for his pioneering work.

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.